Sunday, May 19, 2024 5/19/2024

Pathophysiology of Voice Disorders due to Combination Inhaled Corticosteroids in Asthma

Award Number: R01DC016269
ORGANIZATION: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY/ABSTRACT Over 40 million children and adults in the US suffer from chronic pulmonary diseases including asthma, chronic bronchitis and obstructive pulmonary disease. Asthma alone accounts for 25 million cases, with prevalence increasing by 10% each decade. Combination inhaled corticosteroids (ICs) are the treatment of choice for the long-term management of breathing symptoms. Regrettably, ICs are also associated with voice disorders in up to 50% of cases. These disorders become chronic, impair communication, and have significant adverse occupational, financial, and psychosocial consequences. Given the prevalence of voice disorders associated with combination ICs since chlorofluorocarbon-propelled inhalers were banned in 2008, compelling clinical evidence necessitates a new research initiative to address this critical threat to public health. The long-term goal of this research program is to prevent and cure voice disorders associated with combination ICs across the lifespan. Children placed on inhalers face lifelong, possibly permanent communication impairment. Determining the pathophysiology of IC-related voice disorders is the critical next step to developing new voice-sparing asthma drugs. It is essential to determine the pathophysiology of voice disorders associated with combination ICs, to treat, reverse, and prevent these voice changes. This project accomplishes these objectives in 3 hypothesis-driven aims. Aim 1 determines structural laryngeal biomarkers of IC use associated with voice disorders in children and adults with the 2 most common phenotypes of asthma (high TH2 allergic and low TH2 primarily eosinophilic). Aim 2 quantifies voice disorder onset and reversibility for ICs versus sham using an in vivo animal model. Aim 3 examines the pathogenesis of IC-related voice disorders via examination of cytokines associated with inflammation (IL-1ß, IL-6, TNF-a) from animal true vocal folds and human false vocal folds. Collectively, these aims define the pathophysiology associated with IC-related voice disorders, laying the foundation for voice disorder cure and prevention in this population. This translational project will have immediate and significant clinical implications, making a powerful and sustained impact in the field of communication disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Research Related to Deafness and Communication Disorders	002	6	4/2/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2024	2022	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Research Related to Deafness and Communication Disorders	001	6	3/5/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$323,503
2024	2021	BRIGHAM YOUNG UNIVERSITY	A-153 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	4	3/5/2024	NON-COMPETING CONTINUATION	-$323,503
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $84,399 )
2023	2022	BRIGHAM YOUNG UNIVERSITY	A-153 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	5	8/29/2023	NON-COMPETING CONTINUATION	-$366,075
2023	2022	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Research Related to Deafness and Communication Disorders	001	6	8/30/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$450,474
														Subtotal = $84,399

Issue Date FY: 2022 ( Subtotal = $366,075 )
2022	2022	BRIGHAM YOUNG UNIVERSITY	A41 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	5	5/5/2022	NON-COMPETING CONTINUATION	$366,075
														Subtotal = $366,075

Issue Date FY: 2021 ( Subtotal = $534,766 )
2021	2021	BRIGHAM YOUNG UNIVERSITY	A41 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	4	4/19/2021	NON-COMPETING CONTINUATION	$534,766
														Subtotal = $534,766

Issue Date FY: 2020 ( Subtotal = $531,766 )
2020	2020	BRIGHAM YOUNG UNIVERSITY	A41 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	3	5/5/2020	NON-COMPETING CONTINUATION	$531,766
														Subtotal = $531,766

Issue Date FY: 2019 ( Subtotal = $591,724 )
2019	2019	BRIGHAM YOUNG UNIVERSITY	A-41 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	2	4/18/2019	NON-COMPETING CONTINUATION	$591,724
														Subtotal = $591,724

Issue Date FY: 2018 ( Subtotal = $546,818 )
2018	2018	BRIGHAM YOUNG UNIVERSITY	A-41 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	001	1	6/15/2018	NEW	-$2,311
2018	2018	BRIGHAM YOUNG UNIVERSITY	A-41 ASB	PROVO	UT	84602	UTAH	USA	Research Related to Deafness and Communication Disorders	000	1	5/11/2018	NEW	$549,129
														Subtotal = $546,818

Grand Total All Awards = $2,655,548

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pathophysiology of Voice Disorders due to Combination Inhaled Corticosteroids in Asthma

Award Number: R01DC016269

ORGANIZATION: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer